肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

柳素玲：乳腺肿瘤干细胞机制与调控研究及其临床应用

2015-05-08 佚名 生物谷

乳腺癌干细胞
关注

2015年5月7日，由生物谷主办的2015肿瘤干细胞转化医学论坛在上海好望角大酒店隆重开幕。中国科学技术大学生命科学学院柳素玲教授参加了此次会议，并给我们带来了精彩万分的演讲报告，她的演讲主题是《乳腺肿瘤干细胞机制与调控研究及其临床应用》。柳教授主要从事乳腺肿瘤干细胞的分离鉴定和调控研究，为靶向肿瘤干细胞的药物研发提供理论基础。在报告中柳教授为我们展示了她的研究成果：1.对ALDH+和CD24-C

2015年5月7日，由生物谷主办的2015肿瘤干细胞转化医学论坛在上海好望角大酒店隆重开幕。中国科学技术大学生命科学学院柳素玲教授参加了此次会议，并给我们带来了精彩万分的演讲报告，她的演讲主题是《乳腺肿瘤干细胞机制与调控研究及其临床应用》。柳教授主要从事乳腺肿瘤干细胞的分离鉴定和调控研究，为靶向肿瘤干细胞的药物研发提供理论基础。

在报告中柳教授为我们展示了她的研究成果：

1.对ALDH+和CD24-CD44+干细胞群体进行分析，及检测不同表面标记单细胞成瘤能力的差异。

2.发现MicroRNA100在抑制肿瘤干细胞有明显作用，是一个潜在的靶点药物。

3.通过小分子筛选，柳教授还发现很多小分子，如Repertaxin等对抑制肿瘤干细胞起到显著的抑制作用，是潜力靶标药物。

4.最后柳教授指出，靶向肿瘤干细胞的新型治疗策略研究及药物开发对肿瘤的临床治疗起到重要作用。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2028097, encodeId=a4ab202809e07, content=<a href='/topic/show?id=096123e95c5' target=_blank style='color:#2F92EE;'>#乳腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23795, encryptionId=096123e95c5, topicName=乳腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Sep 12 19:54:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35094, encodeId=94d035094b8, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:08:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835590, encodeId=940b1835590df, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Sep 02 00:54:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23174, encodeId=4f09231e4aa, content=OK, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c1f1624528, createdName=why1269485891, createdTime=Mon May 11 23:22:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22975, encodeId=d3c9229e5b5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri May 08 22:20:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22960, encodeId=0b3c22960b1, content=看过了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Fri May 08 21:55:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
    2015-09-12 yangpeizhi

    #乳腺肿瘤#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2028097, encodeId=a4ab202809e07, content=<a href='/topic/show?id=096123e95c5' target=_blank style='color:#2F92EE;'>#乳腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23795, encryptionId=096123e95c5, topicName=乳腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Sep 12 19:54:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35094, encodeId=94d035094b8, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:08:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835590, encodeId=940b1835590df, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Sep 02 00:54:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23174, encodeId=4f09231e4aa, content=OK, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c1f1624528, createdName=why1269485891, createdTime=Mon May 11 23:22:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22975, encodeId=d3c9229e5b5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri May 08 22:20:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22960, encodeId=0b3c22960b1, content=看过了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Fri May 08 21:55:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
    2015-08-06 hlycom3356

    期待有更多研究

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2028097, encodeId=a4ab202809e07, content=<a href='/topic/show?id=096123e95c5' target=_blank style='color:#2F92EE;'>#乳腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23795, encryptionId=096123e95c5, topicName=乳腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Sep 12 19:54:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35094, encodeId=94d035094b8, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:08:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835590, encodeId=940b1835590df, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Sep 02 00:54:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23174, encodeId=4f09231e4aa, content=OK, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c1f1624528, createdName=why1269485891, createdTime=Mon May 11 23:22:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22975, encodeId=d3c9229e5b5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri May 08 22:20:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22960, encodeId=0b3c22960b1, content=看过了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Fri May 08 21:55:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
    2015-09-02 clmlylxy

    #临床应用#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2028097, encodeId=a4ab202809e07, content=<a href='/topic/show?id=096123e95c5' target=_blank style='color:#2F92EE;'>#乳腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23795, encryptionId=096123e95c5, topicName=乳腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Sep 12 19:54:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35094, encodeId=94d035094b8, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:08:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835590, encodeId=940b1835590df, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Sep 02 00:54:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23174, encodeId=4f09231e4aa, content=OK, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c1f1624528, createdName=why1269485891, createdTime=Mon May 11 23:22:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22975, encodeId=d3c9229e5b5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri May 08 22:20:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22960, encodeId=0b3c22960b1, content=看过了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Fri May 08 21:55:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
    2015-05-11 why1269485891

    OK

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2028097, encodeId=a4ab202809e07, content=<a href='/topic/show?id=096123e95c5' target=_blank style='color:#2F92EE;'>#乳腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23795, encryptionId=096123e95c5, topicName=乳腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Sep 12 19:54:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35094, encodeId=94d035094b8, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:08:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835590, encodeId=940b1835590df, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Sep 02 00:54:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23174, encodeId=4f09231e4aa, content=OK, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c1f1624528, createdName=why1269485891, createdTime=Mon May 11 23:22:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22975, encodeId=d3c9229e5b5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri May 08 22:20:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22960, encodeId=0b3c22960b1, content=看过了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Fri May 08 21:55:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
    2015-05-08 huaxipanxing

    看看

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2028097, encodeId=a4ab202809e07, content=<a href='/topic/show?id=096123e95c5' target=_blank style='color:#2F92EE;'>#乳腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23795, encryptionId=096123e95c5, topicName=乳腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Sep 12 19:54:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35094, encodeId=94d035094b8, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:08:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835590, encodeId=940b1835590df, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Sep 02 00:54:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23174, encodeId=4f09231e4aa, content=OK, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c1f1624528, createdName=why1269485891, createdTime=Mon May 11 23:22:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22975, encodeId=d3c9229e5b5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri May 08 22:20:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22960, encodeId=0b3c22960b1, content=看过了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Fri May 08 21:55:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
    2015-05-08 zhouanxiu

    看过了

    0

相关资讯

Breast Cancer Res Treat：紫杉烷-化疗不会增加乳腺癌相关淋巴水肿的风险

背景：紫杉烷化疗治疗乳腺癌与四肢液体潴留有关；然而，它与乳腺癌相关的淋巴水肿的发展尚不清楚。我们试图确定辅助剂基于紫杉烷的化疗是否会增加上肢淋巴水肿或轻度肿胀的风险。方法：对1121例单侧乳腺癌患者进行周长测量前瞻性筛查淋巴水肿。从术前基线上看，淋巴水肿定义为相对体积的变化(RVC)≥10%。轻度肿胀定义为RVC 为5 %- < 10%。通过医疗记录审核获得临床病理特征。Kaplan-Mei

Lancet：过度筛查会影响女性对乳腺癌筛查的选择

乳腺X光筛查可以降低乳腺癌死亡率。然而,大多数女性并不知道筛查也可以筛选到无关紧要的疾病,导致过度诊断和过度治疗。我们旨在调查在辅助治疗中有关乳腺癌的过度筛查信息是否能帮助大约50岁的女性对乳腺筛查做出知情选择。 我们在新南威尔士州开展了一项以社区为基础的，平行分组的随机对照试验，收纳了年龄在48-50岁的女性。通过电话来选取符合要求的女性。如果在过去2年里没接受乳房x光检查,而且没有乳腺癌病史

Euro Radio：乳房断层X线影像合成技术可能有助于乳腺癌的筛查

根据瑞典Lund大学的一项筛选研究，断层X射线影像合成法（Tomosynthesis）对乳腺癌的检出率比传统乳房X光检查高40%。这是第一次用筛查方法与常规乳房钼靶检查进行对比的大规模研究试验。这项3D X射线技术也使受检的女性更为舒服，因为其减轻了一半对乳房的压力。“Malmö乳房断层X射线影像合成法筛查试验”是一项以人群为基础的单臂前瞻性研究，该计划包含了15000名参与者，从中随机

J Natl Cancer Inst：他莫昔芬治疗乳腺癌预后得以改善

先前研究表明，他莫昔芬治疗后乳腺癌患者乳腺密度降低生存状况得以改善，但这种治疗排除了绝经前女性。因此，我们评估了年龄为32-87岁的患者使用他莫昔芬治疗后乳腺密度的改变和乳腺癌死亡数。 本病例对照研究纳入了来自1990-2008年俄勒冈州波特兰的凯撒医疗机构的349位ER阳性乳腺癌患者，其中97名死于乳腺癌（病例组），252位没有乳腺癌相关死亡（对照组），按照年龄和诊断阶段将两组患者进行分配。测

Breast Cancer Res.：低ATM蛋白表达与激素阴性乳腺癌预后不良有关

背景：丝氨酸/苏氨酸蛋白激酶共济失调症突变蛋白(ATM)在维持基因组的完整性上是至关重要的。双链DNA的断裂，ATM磷酸化关键的下调蛋白质包括p53和BRCA1/2，编码着复杂的信号通路参与细胞周期停滞、DNA修复、衰老和凋亡。虽然ATM零星的突变很少发生在乳腺癌，在乳腺癌中其蛋白表达的状态及其临床意义仍不完善。我们的研究旨在调研在激素阳性(HPBC)和激素阴性(HNBC)早期乳腺癌(EBC)中，

Lancet Oncol：PALB2突变的乳腺癌临床结果

PALB2基因的突变易患乳腺癌，但携带PALB2突变的患者的预后尚未确定。一项来自欧洲的研究评估了有PALB2基因的女性乳腺癌患者和那些携带PALB2突变的乳腺癌患者10年生存率的比值比。研究人员在1996年至2012年间，调查了来自波兰的18家医院的浸润性乳腺癌患者，并且这些患者的PALB22基因已经有了两个有害突变（509_510delGA和172_175delTTGT）。对照组招募的4702